Friday, March 26, 2010
Vermillion's OVA1 became the first protein-based in vitro diagnostic multivariate index assay to receive FDA clearance [See PM 09/17/09] and earlier this month it and Quest Diagnostics began marketing OVA1.
In addition, Correlogic is in discussions with the FDA about its OvaCheck test,
Healthlinx, which launched its test called OvPlex in the UK in February, has said that it may launch the test in the US next year, if it receives regulatory approval.
This week, Arrayit said that OvaDx will be the market's first "comprehensive diagnostic for ovarian cancer" and will be targeted to all women over the age of 35.
The webtable shows a breakdown of the country of origin of all participants in the workshops and among the authorship of the resultant papers. Participants represented 21 different countries, of which 15 were Asian. Each workshop had about 40—100 attendees, and the majority of authors work in Asian hospitals. The manuscripts are a wonderful testament to the resources and expertise available in Asia, and we hope they will provide a valuable resource of information to inform practice and provide a foundation for future developments of oncology services throughout the region.
From unwanted interference to indispensable partner - Masterpiece - Issues 35 - Articles - Cancer World - Education & knowledge through people & facts
From unwanted interference to indispensable partner
"Three years after taking up the presidency of Europe’s first international breast cancer coalition, Gloria Freilich faced her most embarrassing moment. It was 1997 and she had started to address a major meeting of oncologists in Lisbon, talking about her new organisation, designed by women for women, called Europa Donna. Then a doctor stood up and challenged her. What right did a layperson, he asked, have to address a thousand oncologists at a medical meeting?..."